
1. General Information
Erlotero 150 mg Tablet contains erlotinib 150 mg, a targeted anticancer medicine. Erlotinib belongs to a group of medicines called tyrosine kinase inhibitors (TKIs). It is primarily used in certain types of non-small-cell lung cancer (NSCLC) and, in combination with gemcitabine, for certain cases of pancreatic cancer.
Erlotinib is a prescription medicine and should be used only under the supervision of a qualified oncologist. The suitability of treatment may depend on the cancer type and, particularly for NSCLC, the presence of specific EGFR mutations.
2. Product Information
- Product Name: Erlotero 150 mg Tablet
- Active Ingredient: Erlotinib 150 mg
- Dosage Form: Tablet
- Therapeutic Category: Anticancer / Targeted Therapy
- Drug Class: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor
- Typical Route: Oral
- Prescription Status: Prescription medicine
The exact manufacturer, packaging, storage requirements and registration status should be confirmed from the product packaging and applicable local regulations.
3. Uses of Erlotero 150 mg
Erlotinib may be prescribed for:
- Non-small-cell lung cancer (NSCLC) with appropriate EGFR mutations.
- Certain cases of advanced or metastatic pancreatic cancer, generally in combination with gemcitabine.
- Treatment selection should be based on the patient's cancer diagnosis, molecular testing and oncologist's assessment.
4. Benefits of Erlotero 150 mg
The potential benefits of erlotinib include:
- Helps slow the growth of certain cancer cells.
- Specifically targets EGFR signaling in cancers where this pathway is driving tumor growth.
- May help control disease progression in appropriately selected patients.
- Can be taken orally, providing a non-injectable targeted-treatment option.
The response to treatment varies between patients and depends on cancer type, mutation status and other clinical factors.
5. Side Effects of Erlotero 150 mg
Like other anticancer medicines, erlotinib can cause side effects. Important possible effects include:
- Skin rash
- Diarrhea
- Loss of appetite
- Nausea
- Vomiting
- Fatigue
- Abdominal discomfort
- Dry or irritated skin
- Changes in liver function tests
Some side effects can be serious. Patients should promptly contact their healthcare professional if they develop severe breathing problems, significant eye symptoms, severe or persistent diarrhea, severe skin reactions, unusual bleeding, or symptoms suggesting liver problems.
6. Common Side Effects
Commonly reported effects may include:
- Acne-like skin rash
- Diarrhea
- Dry skin
- Itching
- Loss of appetite
- Tiredness
- Nausea
- Abdominal pain or discomfort
- Mouth irritation
- Changes in hair or nails
The severity of side effects differs from person to person. Do not discontinue cancer treatment without consulting the treating doctor.
7. How to Use Erlotero 150 mg
Take Erlotero exactly as prescribed by your oncologist.
For erlotinib, administration is generally on an empty stomach, usually at least 1 hour before or 2 hours after food. Swallow the tablet with water and do not crush or chew it unless specifically instructed by a healthcare professional.
If you miss a dose, follow your doctor's or pharmacist's instructions rather than taking an extra dose to compensate.
8. How Erlotero 150 mg Works
Erlotinib blocks the activity of the epidermal growth factor receptor (EGFR) tyrosine kinase.
Some cancer cells have abnormal EGFR signaling that promotes cell growth and survival. By inhibiting this signaling pathway, erlotinib can reduce the growth and multiplication of susceptible cancer cells.
This targeted action is why testing for appropriate EGFR alterations is important when erlotinib is being considered for NSCLC.
9. Safety Advice
Prescription supervision: Use only under the direction of an oncologist.
Pregnancy: Erlotinib may harm an unborn baby. Women who can become pregnant should discuss effective contraception with their healthcare professional.
Breastfeeding: Breastfeeding is generally not recommended during treatment and for an appropriate period afterward; follow your oncologist's advice.
Liver problems: Tell your doctor if you have liver disease. Liver function may need monitoring.
Kidney problems: Inform your healthcare professional about any kidney problems.
Smoking: Smoking can reduce exposure to erlotinib and may reduce its effectiveness. Discuss smoking with your doctor.
Drug interactions: Tell your doctor about all medicines, supplements and herbal products you use. Acid-reducing medicines such as proton-pump inhibitors and some other medicines can affect erlotinib absorption or metabolism.
Eye problems: Seek medical advice for new or worsening eye pain, redness, excessive tearing or vision changes.
Severe skin or breathing symptoms: Seek urgent medical attention for severe skin reactions or new/worsening breathing difficulties.
10. Frequently Asked Questions (FAQs)
Q1. What is Erlotero 150 mg used for?
Erlotero 150 mg contains erlotinib and may be used for certain EGFR-mutated non-small-cell lung cancers and selected cases of pancreatic cancer.
Q2. Is Erlotero 150 mg a chemotherapy medicine?
It is an oral targeted anticancer therapy rather than traditional cytotoxic chemotherapy. It belongs to the EGFR tyrosine kinase inhibitor class.
Q3. Should Erlotero be taken with food?
Erlotinib is generally taken on an empty stomach, at least 1 hour before or 2 hours after food, unless your doctor gives different instructions.
Q4. Can everyone with lung cancer take Erlotero?
No. Its suitability depends on the cancer's characteristics, including relevant EGFR mutation status, previous treatment and the patient's overall medical condition.
Q5. Can I stop Erlotero if I feel better?
No. Continue treatment according to your oncologist's instructions. Stopping treatment without medical advice may affect cancer control.
Q6. What should I do if I experience severe diarrhea?
Contact your healthcare professional promptly, particularly if diarrhea is persistent or accompanied by dehydration or weakness.
Q7. Can Erlotero interact with other medicines?
Yes. Several medicines can interact with erlotinib. Provide your doctor with a complete list of medicines and supplements you take.
Q8. Is Erlotero available for international pharmaceutical supply?
Availability, import requirements and registration differ by country. International supply should comply with the destination country's pharmaceutical regulations and applicable prescription requirements.
11. Substitute for Erlotero 150 mg
Possible alternatives containing erlotinib 150 mg may include other brands or generic versions of erlotinib. A substitute should not be selected solely by brand name.
The appropriate alternative depends on:
- Active ingredient and strength
- Manufacturer
- Regulatory approval in the destination country
- Patient's diagnosis and EGFR status
- Oncologist's treatment plan
A healthcare professional or licensed pharmacist should confirm any substitution.
12. SEO Keywords
Primary Keywords
- Erlotero 150 mg Tablet
- Erlotero 150 mg exporter
- Erlotinib 150 mg Tablet exporter
- Erlotinib 150 mg supplier from India
- Erlotinib 150 mg pharmaceutical exporter
- Erlotero 150 mg medicine supplier
- Erlotero 150 mg wholesale supplier
- Erlotinib 150 mg wholesale exporter
- Erlotinib tablets exporter from India
- Erlotero 150 mg trusted exporter
Long-Tail B2B Keywords
- Buy Erlotero 150 mg Tablets from India
- Erlotinib 150 mg Tablet supplier from Nagpur India
- Erlotero 150 mg pharmaceutical supplier India
- Erlotinib 150 mg tablets wholesale supplier India
- Erlotero 150 mg medicine exporter from Nagpur
- Erlotinib 150 mg oncology medicine exporter India
- Erlotero 150 mg international pharmaceutical supplier
- Erlotinib 150 mg B2B medicine supplier
- Erlotero 150 mg bulk pharmaceutical supplier
- Erlotinib 150 mg cancer medicine exporter India
- Reliable Erlotero 150 mg exporter from India
- Trusted Erlotinib 150 mg pharmaceutical supplier
Country-Focused Keywords
- Erlotero 150 mg supplier to USA
- Erlotero 150 mg exporter to UK
- Erlotero 150 mg supplier to Australia
- Erlotero 150 mg supplier to Singapore
- Erlotero 150 mg exporter to Canada
- Erlotero 150 mg supplier to South Korea
- Erlotero 150 mg exporter to UAE
- Erlotinib 150 mg supplier USA
- Erlotinib 150 mg supplier UK
- Erlotinib 150 mg supplier Australia
- Erlotinib 150 mg supplier Canada
- Erlotinib 150 mg supplier Singapore
- Erlotinib 150 mg supplier South Korea
- Erlotinib 150 mg supplier UAE
Phoenix Exim SEO Keywords
- Phoenix Exim Erlotero 150 mg supplier
- Phoenix Exim Erlotinib 150 mg exporter
- Phoenix Exim oncology medicine exporter India
- Phoenix Exim pharmaceutical exporter Nagpur
- Phoenix Exim Erlotero 150 mg international supplier
- Phoenix Exim Erlotinib 150 mg B2B supplier
- Phoenix Exim cancer medicine exporter from India
Keywords







